Archive for the ‘Stem Cell Worx News’ Category

Doctor Noel Gets His Wish

Saturday, January 25th, 2014
Jared Noel and wife Hannah with their daughter, Elise Alexandra Grace Noel, at their home in New Zealand

Jared Noel and wife Hannah with their daughter, Elise Alexandra Grace Noel, at their home in New Zealand

Every birth is special, but as Dr Jared Noel held his tiny daughter in his arms, he knew the moment was especially precious.

Dr Noel is dying. He was able to survive until her birth only after an outpouring of generosity enabled him to buy an expensive drug that slowed the growth of his cancer.

And as Elise Alexandra Grace Noel was born on January 17, weighing 3.87kg, the proud 33-year-old dad was able not only to meet her but to help deliver her.

“I handed her to (wife) Hannah, cut the cord and then I got to have time with her,” he said.

“It’s a surreal experience. It’s weird just looking at her and thinking, ‘That’s my daughter’. There’s so many mixed emotions. There’s the joy of having a child, against the backdrop of everything else that’s going on. It’s just sinking in how blessed we are to be where we are given our circumstance.”

As reported last year, after a scan in October revealed the bowel cancer he had battled for five years was growing rampantly in his liver, the Auckland City Hospital doctor was told it was unlikely he would live to see 2014.

It was a particularly cruel blow as baby Elise was due in late January.

The couple appealed on the fundraising website Givealittle for donations to help them pay for the drug Avastin, which can slow the growth of tumours, in the hope it would extend Dr Noel’s life long enough for him to meet his daughter.

Their $60,000 target was met within six hours – a record for the fundraising site.

Dr Noel was able to immediately begin a 10-round course of Avastin.

A scan taken after four rounds revealed the lesions in his liver had either stopped growing or significantly reduced in size.

Hannah, a doctor in paediatrics at Waitakere Hospital, said she was “over the moon” at being able to watch her husband with Elise.

It would not have been possible without the support of family, friends and strangers around the world, she said. “I knew he was going to be a great dad and he is. And this is a really precious time.”

Elise was conceived through IVF early last year when Jared’s cancer, while still terminal, was not growing.

Hannah said her focus now was on enjoying the time they had together as a family. “We’re very realistic that that might not be much time. We’re very hopeful we’ll get months. Years would be better but we’ll see. In my mind we’re a family unit so we’re all together in this.”

She had rallied friends and family to support her and help care for Elise after Jared dies. “I don’t think you can ever really prepare yourself for that reality properly. Having said that, I’ve been trying to do that for the past five years and he’s still here and now we’ve got a baby. So I think I really need to enjoy this time that we have, the three of us, and not focus on the time that Jared’s not with us.”

On Wednesday, January, 29th, 2014 Jared will begin his 80th round of chemotherapy and his sixth of Avastin. His greatest hope now is to survive long enough for Elise to have a memory of him.

However, he knows the odds are against him. He is writing a memoir and participating in a documentary with the aim of leaving a legacy for his daughter. “That’s probably the hard thing for me. That she won’t really know me. But hopefully she can know of me.”

 

Source:  Hayden Donnell, NZ Herald

 

Bone Marrow Stem Cells Treat Tuberculosis

Thursday, January 9th, 2014

*  Early study shows adult stem cell infusion can cure superbug TB

*  Some 450,000 people worldwide have drug-resistant TB

LONDON, Jan 9 (Reuters) – Patients with potentially fatal “superbug” forms of tuberculosis (TB) could in future be treated using stem cells taken from their own bone marrow, according to the results of an early-stage trial of the technique.

The finding, made by British and Swedish scientists, could pave the way for the development of a new treatment for the estimated 450,000 people worldwide who have multi drug-resistant (MDR) or extensively drug-resistant (XDR) TB.

In a study in The Lancet medical journal on Thursday, researchers said more than half of 30 drug-resistant TB patients treated with a transfusion of their own bone marrow stem cells were cured of the disease after six months.

“The results show that the current challenges and difficulties of treating MDR-TB are not insurmountable, and they bring a unique opportunity with a fresh solution to treat hundreds of thousands of people who die unnecessarily,” said TB expert Alimuddin Zumla at University College London, who co-led the study.

TB, which infects the lungs and can spread from one person to another through coughing and sneezing, is often falsely thought of as a disease of the past.

In recent years, drug-resistant strains of the disease have spread around the world, batting off standard antibiotic drug treatments.

The World Health Organisation (WHO) estimates that in Eastern Europe, Asia and South Africa 450,000 people have MDR-TB, and around half of these will fail to respond to existing treatments.

TB bacteria trigger an inflammatory response in immune cells and surrounding lung tissue that can cause immune dysfunction and tissue damage.

Bone-marrow stem cells are known to migrate to areas of lung injury and inflammation and repair damaged tissue. Since they also modify the body’s immune response and could boost the clearance of TB bacteria, Zumla and his colleague, Markus Maeurer from Stockholm’s Karolinska University Hospital, wanted to test them in patients with the disease.

In a phase 1 trial, 30 patients with either MDR or XDR TB aged between 21 and 65 who were receiving standard TB antibiotic treatment were also given an infusion of around 10 million of their own stem cells.

The cells were obtained from the patient’s own bone marrow, then grown into large numbers in the laboratory before being re-transfused into the same patient, the researchers explained.

Although a phase 1 trial is primarily designed only to test a treatment’s safety, the scientists said further analyses of the results showed that 16 patients treated with stem cells were deemed cured at 18 months compared with only five of 30 TB patients not treated with stem cells.

Maeurer stressed that further trials with more patients and longer follow-up were needed to better establish how safe and effective the stem cell treatment was.